FDA Advisers Unanimously Back J&J Hepatitis C Drug - WBOC-TV 16, Delmarvas News Leader, FOX 21 -

FDA Advisers Unanimously Back J&J Hepatitis C Drug

Posted:

SILVER SPRING, Md. (AP) - An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.
    
All 19 members of a panel of Food and Drug Administration advisers voted unanimously in favor of approving J&J's simeprevir, a daily pill designed to eliminate the most common form of hepatitis C.
    
The FDA is not required to follow the group's recommendation, though it often does. A decision on the drug is expected next month.
    
More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year. J&J is one of a half-dozen companies working to develop more effective treatments for the virus.

Powered by WorldNow

All content © Copyright 2000 - 2014 Worldnow and WBOC. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service